Focused on endocrine disorders, this biopharmaceutical firm develops therapies for rare endocrine diseases and endocrine-related cancers. Its lead candidate targets acromegaly and carcinoid syndrome, attracting investor interest in its late-stage pipeline.
2 members of Congress have disclosed 5 trades in Crinetics Pharmaceuticals, Inc. (CRNX), a Healthcare company. The buy/sell breakdown shows 4 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-03-03 | Gilbert Cisneros | buy | $1K – $15K |
| 2025-04-17 | Gilbert Cisneros | buy | $1K – $15K |
| 2025-03-19 | Josh Gottheimer | sell | $1K – $15K |
| 2025-01-29 | Gilbert Cisneros | buy | $1K – $15K |
| 2024-09-25 | Josh Gottheimer | buy | $1K – $15K |